Orforglipron taken orally once daily leads to significant body weight loss (ATTAIN-1 Study) - EurekAlert!
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
